HanAll Biopharma

Hanall biopharma email format

Verified email-pattern data for Hanall Biopharma is currently limited. You can still use the company insights and contact sections below.
HanAll Biopharma (KRX: 009420.KS) is a global biopharmaceutical company with a presence in Korea, the USA, Japan, and Indonesia, with a mission to make meaningful contributions to patients' lives by introducing innovative, impactful medicines to address severe unmet medical needs. HanAll has been operating a portfolio of pharmaceutical products in areas ranging from endocrine, circulatory, and urologic diseases for 50 years. HanAll has also expanded its focus to ophthalmology, immunology, oncology, and neurology to discover and develop innovative medicines for patients with diseases for which there are no effective treatments. Its lead pipeline asset, HL161 (INN: batoclimab), an anti-FcRn antibody, is being developed in Phase 3 and Phase 2 trials worldwide for the treatment of autoimmune diseases, including myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP), and Graves’ disease (GD). Another key asset, HL036 (INN: tanfanercept), a TNF-alpha inhibitor protein, is being evaluated in Phase 3 clinical studies in the US and China for the treatment of dry eye disease.

Company Details

Employees
52
Founded
-
Address
12 Bongeunsa-Ro 114-Gil, Daewoong Building 3f,korea, Republic Of
Phone
306-81-05479
Email
in****@****l.co.kr
Industry
Biotechnology Research
Website
hanall.com
HQ
Seoul, Gangam-gu
Looking for a particular HanAll Biopharma employee's phone or email?

Hanall Biopharma Questions

Top HanAll Biopharma Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant